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Original Article 
Temporal trends and outcomes of acute myocardial infarction in 
patients with cancer
Naga Venkata Pothineni1, Nishi N. Shah1, Yogita Rochlani2, Marwan Saad1, Swathi Kovelamudi1, 
Konstantinos Marmagkiolis3, Sabha Bhatti1, Mehmet Cilingiroglu4, Wilbert S. Aronow2, Abdul Hakeem1,5
1Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA; 2Division of Cardiology, Westchester Medical 
Center and New York Medical College, Valhalla, New York, USA; 3Department of Cardiology, Florida Hospital, Zephyrhills, Florida, USA; 
4Department of Cardiology, Arkansas Heart Hospital, Little Rock, Arkansas, USA; 5Division of Cardiovascular Medicine, Department of Internal 
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Background: Data on outcomes of ST-elevation myocardial infarction (STEMI) in patients with cancer 
are scarce. We investigated the nationwide trends in admissions for STEMI, utilization of percutaneous 
coronary intervention (PCI), and in-hospital outcomes in patients with the three most common cancer 
diagnoses (lung, breast, and colon) compared to patients without cancer. 
Methods: We conducted an administrative database study using the Nationwide Inpatient Sample (NIS). 
All in-patient hospitalizations for STEMI from 2001 to 2011 were identified. Patients with concomitant 
diagnosis of lung, breast or colon cancer were identified using appropriate International classification of 
diagnosis (ICD 9-CM) codes. Primary outcome was utilization of PCI and in-hospital mortality in patients 
with cancer compared to those without cancer.
Results: Utilization of PCI was 30.8% (1,191/3,871), 20.2% (4,541/22,480) and 17.3% (1,716/9,944) in 
patients with breast, lung and colon cancer, respectively. Among patients without any of these cancers, use of 
PCI was 49.6%. In-hospital mortality was highest in patients with lung cancer (57.1%) and lowest in patients 
without cancer (25.7%).
Conclusions: Patients with cancer have significantly worse in-hospital mortality compared to those 
without cancer, partly due to a relatively lower rate of PCI utilization in cancer patients with STEMI.
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Introduction
Recent advances in cancer therapy have led to a significant 
decline in cancer-related mortality. It is estimated that 
there would be around 18 million cancer survivors in the 
United States by 2020 (1). Improvement in life expectancy 
in cancer patients, however, has led to an increase in burden 
of cardiovascular disease in this cohort of patients, partly 
related to comorbidities and partly due to the use of cardio 
toxic chemotherapeutic regimens. This has led to the 
inception of cardio-oncology, with many centers developing 
subspecialty programs to cater to the growing need of 
these patients. However, the exclusion of cancer patients 
from cardiovascular clinical trials and heart disease patients 
from oncology investigations has resulted in a paucity of 
data to direct clinical decision-making in many cardio-
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oncology patients (2). Further, patients with cancer present 
with multiple comorbidities such as coagulopathy and 
thrombocytopenia which make incorporation of existing 
guideline -based treatments challenging. We sought to 
identify trends in admissions for ST-elevation myocardial 
infarction (STEMI), utilization of percutaneous coronary 
intervention (PCI) and in-hospital outcomes in patients 
with three common cancers (lung, breast, colon) compared 
to patients without cancer. 
Methods
We used the Nationwide Inpatient Sample (NIS) to identify 
all admissions with ST elevation myocardial infarction 
(ICD 9 code 410) from the years 2001–2011. The NIS is 
part of the Agency for Health Care Research and Quality's 
Healthcare Cost and Utilization Project (HCUP) and is 
the largest all-payer inpatient care database in the United 
States, containing data on >7 million hospital stays. It 
contains data related to hospital admission and discharge 
from a 20% stratified sample of community hospitals in 
the United States (3). We used the clinical classification 
software developed by HCUP to identify the clinical 
variables for our analyses. Using this dataset, patients 
with STEMI and a concurrent diagnosis of lung cancer, 
colon cancer and breast cancer were identified. A cohort of 
patients admitted for STEMI without any of these cancer 
diagnoses was identified as the non-cancer group. We 
evaluated utilization of PCI (angioplasty and/or stenting) 
and in-hospital outcomes in STEMI patients with various 
cancers. All statistical analyses were done using SAS 
9.4 (Cary, NC).
Results 
There were 3,794,385 STEMI admissions during the study 
period from 2001 to 2011 of which 5,552 (0.15%) patients 
had active breast cancer, 31,246 (0.82%) had lung cancer 
and 12,015 (0.32%) patients had colon cancer. Trends in 
STEMI admissions have been declining in the general 
population and patients with lung cancer, whereas patients 
with breast and colon cancer demonstrated a stable trend 
(Figure 1). Utilization of PCI was 30.8% (1,191/3,871), 
20.2% (4,541/22,480), and 17.3% (1,716/9,944) in 
patients with breast, lung and colon cancer, respectively 
(Table 1). Comparatively, among patients without any of 
these cancers, use of PCI was 49.5%. In-hospital mortality 
was highest in patients with lung cancer (57.1%) and lowest 
in patients without cancer (25.7%) with no significant 
difference in trends (Figure 1). Utilization of PCI favorably 
impacted in-hospital mortality in all patients’ groups 
(Figure 2).
Discussion
In the present study, we report a significant incidence of 
STEMI in patients with the three most prevalent cancers 
in the United States. Although the incidence of STEMI 
has been declining in the general population, incidence in 
patients with breast and colon cancer has remained steady. 
We also report a significant disparity in utilization of PCI 
in patients with cancer presenting with STEMI compared 
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Figure 1 Graphical trends in STEMI incidence and in-hospital mortality in patients with and without cancer between 2001–2011. (A) 
Trends in STEMI incidence from 2001–2011 among patients with various cancers (primary vertical axis) and general population without 
cancer (secondary vertical axis); (B) trends in STEMI in-hospital mortality from 2001–2011. STEMI, ST-elevation myocardial infarction.
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to the general population. Overall in-hospital mortality was 
substantially higher in patients with cancer compared to the 
non-cancer cohort. Even in the cancer cohort, utilization of 
PCI had a substantial impact on immediate outcomes with 
higher rates of in-hospital mortality in patients in whom 
PCI was deferred. This could represent a wide practice 
variation in the implementation of life saving therapies in 
patients with cancer. 
Coronary artery disease is a frequent comorbidity in 
patients with various cancers. This is explained partly by 
the improvement in therapeutic modalities for cancer 
that prolong life expectancy and in part by direct cardiac 
and vascular toxic effects of chemotherapy and radiation. 
In addition, cancer patients have a hypercoagulable state 
that predisposes to acute thrombotic events. Data on 
outcomes of cancer patients with STEMI is sparse due to 
the exclusion of these patients from randomized clinical 
trials. A few existing registry studies have reported higher 
mortality rates in patients with cancer presenting with acute 
coronary syndrome. Velders et al. reported a multi-center 
study from the Netherlands on outcomes of STEMI in 
patients with cancer (4). In this prospective registry, patients 
with cancer had a higher incidence of cardiovascular 
comorbidities such as peripheral vascular disease, renal 
insufficiency and cerebrovascular disease. Use of drug-
eluting stents and glycoprotein IIb/IIIa inhibitors was 
significantly lower in patients with cancer. Patients with 
cancer who had STEMI had significantly higher all-cause 
mortality at 1-year follow-up compared with those without 
a history of cancer (in-hospital 9.1% vs. 3.4%, 1-year 17.4% 
vs. 6.5%). More importantly, this difference in mortality 
was primarily driven by a higher incidence of cardiac death 
in cancer patients (in-hospital 8.7% vs. 3.4%, 1-year 10.7% 
vs. 5.4%). The presence of cancer, specifically diagnosed 
in 6 months preceding the STEMI, was an independent 
risk factor for increased cardiac and all-cause mortality at 
7 days on multivariate analysis (adjusted hazard ratio =3.34; 
95% CI, 1.57–7.08). In a small observational series from 
Japan, Kurisu et al. compared outcomes of acute MI in 
patients with and without cancer and showed no difference 
in coronary revascularization, discharge medications, stent 
selection or cardiovascular outcomes between the two 
groups (5). Yusuf et al. reported a single center experience 
outcomes of 456 cancer patients with an acute coronary 
syndrome (STEMI 15%) over a 6-year study period (6). 
In their series, PCI was utilized in only 3.3% of cancer 
patients, and  the 1-year mortality was 78% in patients with 
STEMI (6).
Patients with active cancer presenting with STEMI 
represent a challenging cohort. Complications related to the 
underlying cancer such as coagulopathy, thrombocytopenia, 
anemia, organ dysfunction, and anticipation of other 
therapeutic procedures factor into clinical decision making. 
Patients with advanced cancer are particularly challenging 
as long-term goals of care have to be considered. In a recent 
expert consensus statement on the management of cancer 
patients in the catheterization lab, it was recommended 
Table 1 Utilization of PCI and in-hospital mortality in STEMI patients with and without cancer
Variables
Breast cancer (N=3,871) (%) Lung cancer (N=22,480) (%) Colon cancer (N=9,944) (%) No cancer (N=2,990,913) (%)
PCI No PCI PCI No PCI PCI No PCI PCI No PCI
No. of 
patients
1,191 (30.8) 2,680 (69.2) 4,541 (20.2) 17,939 (79.8) 1,716 (17.3) 8,228 (82.7) 1,483,706 (49.6) 1,507,207 (50.4)
In-hospital 
mortality
90 (7.6) 747* (27.9) 698 (15.4) 7,484* (41.7) 178 (10.4) 2,693* (32.7) 58,037 (3.9) 328,762* (21.8)
*, represents that there is a statistically significant difference in mortality between the PCI and no PCI groups with a P value of <0.001. 
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

































Figure 2 In-hospital mortality in patients with various cancers and 
general population based on PCI utilization. *, P<0.001 for all of 
the above comparisons in the chart. PCI, percutaneous coronary 
intervention.
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to consider PCI in cancer patients with STEMI and high 
risk non-STEMI even when life expectancy is <1 year and 
to use drug-eluting stents if the platelet count is above 
30,000/mL (7). In addition to prolonging survival, 
revascularization may also be a palliative option to control 
symptoms in patients with severe angina pectoris.
Our study is the largest one reporting contemporary 
outcomes of STEMI in cancer patients. Strengths of our 
study include analysis of a nationwide cohort over a decade 
and a large sample size. However, we acknowledge several 
limitations. Data on cancer stage, treatment strategies, 
hematological parameters, and anticipated procedures were 
not available. All these factors may play a significant role in 
decision making regarding PCI. We assessed only in-hospital 
mortality, and data on long-term outcomes were unavailable. 
In summary, we report a relatively lower rate of PCI 
utilization in cancer patients with STEMI. With lack of 
clinical trial data on management of STEMI in patients 
with various cancers and with improvements in cancer 
survivors overall, further studies are required to identify 
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